+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Inclisiran"

Coronary Artery Disease Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028) - Product Thumbnail Image

Coronary Artery Disease Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • Report
  • April 2023
  • 129 Pages
  • Global
From
Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 63 Pages
  • Global
From
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 243 Pages
  • Global
From
Loading Indicator

Inclisiran is a cardiovascular drug that is used to reduce the risk of cardiovascular events in adults with established cardiovascular disease. It is a small interfering RNA (siRNA) drug that works by blocking the production of a protein called PCSK9, which is involved in the regulation of cholesterol levels. Inclisiran is administered as a subcutaneous injection, and is typically given twice a year. The Inclisiran market is composed of pharmaceutical companies that develop, manufacture, and market the drug. Companies in this market include Novartis, The Medicines Company, and Alnylam Pharmaceuticals. These companies are focused on providing innovative treatments for cardiovascular diseases, and are actively researching and developing new therapies to improve patient outcomes. Show Less Read more